India’s drug advisory body is re-evaluating the doorstep delivery of medicines, initially permitted during the Covid-19 pandemic. This review follows concerns raised by the All-India Organisation of Chemists and Druggists, alleging misuse and increased unauthorized sales of prescription drugs. While the DTAB discussed the matter in April 2025, its final decision remains unclear, prompting debate after the pandemic’s end.
